Oklahoma City, OK – (March 14, 2017) Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories.

Oklahoma City, OK – (January 13, 2017) Cytovance® Biologics, Inc., a leading full service biopharmaceutical contract manufacture of mammalian and microbial biologics, today announced the addition of Mike O’Mara as Sr. Vice President of Manufacturing Operations

OKLAHOMA CITY, OK --(Marketwired - November 29, 2016) - Cytovance® Biologics, Inc., a leading full service contract manufacturer of mammalian and microbial biologics, today announced the addition of Joyce Johnson as Vice President of Human Resources.

Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE, NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.

Cytovance® Biologics, Inc., announced today that they have entered into a definitive agreement by which Hepalink USA Inc. will acquire Cytovance® Biologics Inc., a leading biopharmaceutical contract development manufacturing company.

Cytovance® Biologics, Inc., a leading full-service contract development and manufacturer of mammalian and microbial biologics, announces that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions.

Oklahoma City, OK-Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company is gearing up for The BioInnovation Summit in London, UK February 10-11, 2015. Jesse McCool, Ph.D., will present on one of Cytovance’s open innovation projects, the Keystone Expression System™